July 19, 2018

Siemens Healthcare Diagnostics Inc. Matthew Gee   
Senior Manager, Regulatory Affairs 511 Benedict Avenue   
Tarrytown, NY 10591

Re: K171566 Trade/Device Name: Atellica IM High-Sensitivity Troponin I (TnIH) Regulation Number: 21 CFR 862.1215 Regulation Name: Creatine phosphokinase/creatine kinase or isoenzymes test system Regulatory Class: Class II Product Code: MMI Dated: June 26, 2018 Received: June 27, 2018

Dear Matthew Gee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR

Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

![](images/2c25ee050d8c36f39546c6b7ba225d3bae386ca372ebd36b1805d95988be6921.jpg)

Courtney H. Lias, Ph.D.GPS Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of 21 CFR 807.92 and the Safe Medical Device Act of 1990.

The assigned 510(k) Number is: K171566

1. Date Prepared July 13, 2018

# 2. Applicant Information

Contact: Matthew Gee, M.Sc. Senior Manager, Regulatory Affairs

Address:

Phone: Fax: Email:

# 3. Regulatory Information

Table 1. Regulatory Information for Atellica IM High-Sensitivity Troponin I (TnIH)   

<table><tr><td>Trade Name</td><td>Atellica® IM High-Sensitivity Troponin I (TnIH)</td></tr><tr><td>Model Numbers</td><td>10997840 (1-pack); 10997841 (5-pack)</td></tr><tr><td>Common Name</td><td>Immunoassay Method, Troponin Subunit</td></tr><tr><td>Regulation Number</td><td>862.1215</td></tr><tr><td>Regulation Description</td><td>Creatine phosphokinase /creatine kinase or isoenzymes test system</td></tr><tr><td>Product Code</td><td>MMI</td></tr><tr><td>FDA Classification</td><td>Class II</td></tr><tr><td>Review Panel</td><td>Clinical Chemistry (75)</td></tr></table>

# 4. Predicate Device Information

Predicate Device Name: Elecsys Troponin T Gen 5 STAT Immunoassay 510(k) Number: K162895

# 5. Intended Use / Indications for Use

The Atellica® IM High-Sensitivity Troponin I (TnIH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human serum or plasma (lithium heparin) using the Atellica® IM Analyzer. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).

# 6. Device Description

Table 2. Summary of Ingredients of the Atellica IM TnIH Assay Components

<table><tr><td>Component</td><td>Volume</td><td>Ingredients</td></tr><tr><td colspan="3">Atellica IM TnlH Primary Reagent ReadyPack (included in assay kit)</td></tr><tr><td>Atellica IM TnlH Lite Reagent</td><td>8.0 mL/pack</td><td>Bovine serum albumin (BSA) conjugated to a recombinant monoclonal (sheep) Fab anti-human cTnl (~0.2—0.4 µg/mL) labeled with acridinium ester in HEPES buffer; stabilizers; preservatives</td></tr><tr><td>Atellica IM TnlH Solid Phase Reagent</td><td>13.0 mL/pack</td><td>Streptavidin-coated magnetic latex particles (0.45 mg/mL) with 2 biotinylated (mouse and sheep) monoclonal anti-troponin I antibodies in buffer; stabilizers; preservatives</td></tr><tr><td colspan="3">Atellica IM TnlH Calibrator (included in assay kit)</td></tr><tr><td>Atellica IM TnIH High Calibrator (Cal H)</td><td>1.0 mL/vial (lyophilized)</td><td>Human serum; human cTnl; preservatives</td></tr><tr><td>Atellica IM TnIH Low Calibrator (Cal L)</td><td>1.0 mL/vial</td><td>HEPES buffer; bovine serum albumin (BSA); surfactants; preservatives</td></tr></table>

# 7. Purpose of the Submission

The purpose of this premarket notification is to submit a new device (Atellica IM TnIH) to FDA for consideration for clearance.

# 8. Comparison of Predicate Device and Modified Device

Table 3. Comparison of Atellica IM TnIH Assay to Predicate   

<table><tr><td>Item</td><td>Atellica IM TnlH (Candidate Device)</td><td>Elecsys Troponin T Gen 5 STAT Immunoassay (Predicate Device)</td></tr><tr><td>Intended Use</td><td>The Atellica® IM High-Sensitivity Troponin I (TnlH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human serum or plasma using the Atellica® IM Analyzer. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).</td><td>Immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in lithium heparin plasma. The immunoassay is intended to aid in the diagnosis of myocardial infarction. The electrochemiluminescence immunoassay &quot;ECLIA&quot; is intended for use on the cobas system</td></tr><tr><td>Indications for Use</td><td>The assay can be used to aid in the diagnosis of acute myocardial infarction aid in the diagnosis of myocardial</td><td>analyzers. The immunoassay is intended to</td></tr><tr><td>Methodology</td><td>(AMI). Chemiluminescence</td><td>infarction. Electrochemiluminescence</td></tr><tr><td>Assay Protocol</td><td>Sandwich immunoassay</td><td>Same</td></tr><tr><td>Analyte</td><td>Cardiac troponin I</td><td>Cardiac troponin T</td></tr><tr><td>Specimen Type</td><td>Lithium heparin plasma and serum</td><td>Lithium heparin plasma</td></tr><tr><td>Lower Limit of Measuring Range</td><td>LoQ</td><td>Same</td></tr></table>

Table 3. Comparison of Atellica IM TnIH Assay to Predicate   

<table><tr><td>Item</td><td>Atellica IM TnIH (Candidate Device)</td><td>Elecsys Troponin T Gen 5 STAT Immunoassay (Predicate Device)</td></tr><tr><td>Measuring Range</td><td>2.50-25,000 pg/mL (ng/L)</td><td>6.0-10,000 pg/mL (ng/L)</td></tr><tr><td>Upper 99th Percentile Cutoff</td><td>Female-Lithium Heparin: 34.11 pg/mL Male-Lithium Heparin: 53.48 pg/mL Combined-Lithium Heparin: 45.20 pg/mL Female-Serum: 38.64 pg/mL Male-Serum: 53.53 pg/mL Combined-Serum: 45.43 pg/mL Overall: 45.20 pg/mL</td><td>Female: 14 pg/mL (ng/L) Male: 22 pg/mL (ng/L) Combined: 19 pg/mL (ng/L)</td></tr><tr><td>Calibration</td><td>2-point calibration</td><td>Same</td></tr></table>

# 9. Standard/Guidance Document References

The following recognized standards from Clinical Laboratory Standards Institute (CLSI) were used as a basis of the study procedures described in this submission:

Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline – Third Edition (CLSI EP05-A3, 2014; Recognition No. 7-251) Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (CLSI EP06-A, 2003; Recognition No. 7-193) Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition (CLSI EP07-A2, 2005; Recognition No. 7-127)   
Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition (CLSI EP17-A2, 2012; Recognition No. 7-233) Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition (CLSI EP28-A3c – formerly C28-A3c, 2010; Recognition No. 7-224)   
Medical devices – Application of risk management to medical devices   
(ANSI/AAMI/ISO 14971:2007/(R)2010; Recognition No. 5-70)

# 10. Performance Characteristics

# 10.1 Precision

A 20-day precision study was performed according to CLSI EP5-A3. Samples included eight (8) samples (4 serum; 4 lithium heparin plasma) from AMI patients. These samples were diluted with native serum or lithium heparin plasma from healthy subjects. Samples were assayed twice a day in replicates of 2, for 20 days $[ n = 8 0$ replicates per sample). Testing was performed on 2 instruments. The following are representative of the results obtained:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>SD(pg/mL)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(pg/mL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>12.72</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>127.93</td><td rowspan=1 colspan=1>2.30</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>3.09</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>1334.97</td><td rowspan=1 colspan=1>22.28</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>27.48</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Serum 4</td><td rowspan=1 colspan=1>13815.89</td><td rowspan=1 colspan=1>192.05</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>266.91</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin Plasma 1</td><td rowspan=1 colspan=1>12.03</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin Plasma 2</td><td rowspan=1 colspan=1>131.21</td><td rowspan=1 colspan=1>2.23</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.75</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin Plasma 3</td><td rowspan=1 colspan=1>1363.38</td><td rowspan=1 colspan=1>27.11</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>32.00</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin Plasma 4</td><td rowspan=1 colspan=1>12862.97</td><td rowspan=1 colspan=1>212.91</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>291.00</td><td rowspan=1 colspan=1>2.3</td></tr></table>

# 10.2 Linearity

Two linearity studies were performed according to CLSI EP06-A, each using 9 samples prepared by mixing a high-spiked cTnI sample with a low cTnI sample. The first study spanned the assay range and the second study ranged to $\sim 1 5 0 ~ \mathsf { p g / m L }$ . Each study was tested with lithium heparin plasma and serum. The mean was taken from each sample tested in duplicate. The following are representative of the results obtained:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=1 colspan=4>Deviation from Linear Fit (% or pg/mL)</td></tr><tr><td rowspan=1 colspan=1>Li HepFull Range</td><td rowspan=1 colspan=1>SerumFull Range</td><td rowspan=1 colspan=1>Li Hep~150 pg/mL</td><td rowspan=1 colspan=1>Serum~150 pg/mL</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>-0.53%</td><td rowspan=1 colspan=1>0.27%</td><td rowspan=1 colspan=1>2.23%</td><td rowspan=1 colspan=1>0.73%</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>3.26%</td><td rowspan=1 colspan=1>-6.46%</td><td rowspan=1 colspan=1>-0.07%</td><td rowspan=1 colspan=1>-0.04%</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>2.08%</td><td rowspan=1 colspan=1>-4.50%</td><td rowspan=1 colspan=1>-0.11%</td><td rowspan=1 colspan=1>-0.06%</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>0.78%</td><td rowspan=1 colspan=1>-2.95%</td><td rowspan=1 colspan=1>-0.09%</td><td rowspan=1 colspan=1>-0.05%</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>-0.01%</td><td rowspan=1 colspan=1>-0.27%</td><td rowspan=1 colspan=1>-0.04%</td><td rowspan=1 colspan=1>-0.03%</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>-1.40%</td><td rowspan=1 colspan=1>1.20%</td><td rowspan=1 colspan=1>0.01%</td><td rowspan=1 colspan=1>-0.01%</td></tr><tr><td rowspan=1 colspan=1>G</td><td rowspan=1 colspan=1>-2.49%</td><td rowspan=1 colspan=1>3.24%</td><td rowspan=1 colspan=1>0.07%</td><td rowspan=1 colspan=1>0.01%</td></tr><tr><td rowspan=1 colspan=1>H</td><td rowspan=1 colspan=1>-3.50%</td><td rowspan=1 colspan=1>5.43%</td><td rowspan=1 colspan=1>0.13%</td><td rowspan=1 colspan=1>0.03%</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>-4.58%</td><td rowspan=1 colspan=1>7.47%</td><td rowspan=1 colspan=1>0.19%</td><td rowspan=1 colspan=1>0.06%</td></tr></table>

# 10.3 Dilution Recovery

Eight (8) native AMI samples (4 lithium heparin plasma and 4 serum) measuring above the analytical measuring range (i.e. $> 2 5 0 0 0 ~ \mathsf { p g / m L } )$ were diluted to 1:2 and 1:5 with Multi-Diluent 11. Recoveries for individual samples were all within $20 \%$ . The mean of all 1:2 dilutions was $9 9 . 6 \%$ . The mean of all 1:5 dilutions was $91 . 6 \%$ .

# 10.4 Hook Effect

A study was performed to evaluate hook effect. There is no hook effect with the Atellica IM TnIH assay up to $5 0 0 , 0 0 0 ~ { \mathsf { p g / m L } }$ .

# 10.5 Detection Limit

The limit of blank (LoB), limit of detection (LoD), and the limit of quantitation (LoQ) were determined as described in CLSI protocol EP17-A2. The Atellica IM TnIH assay has an LoB of $0 . 5 0 \ : \mathsf { p g / m L }$ , an LoD of $1 . 6 0 ~ \mathsf { p g / m L }$ , and an LoQ of $2 . 5 0 ~ { \mathsf { p g / m L } }$ .

The LoB is defined as the highest measurement result that is likely to be observed for a blank sample. The LoD is defined as the lowest concentration of cardiac troponin I that can be detected with $9 5 \%$ probability. The LoQ is defined as the lowest concentration of cardiac troponin I that can be detected at a total CV of $20 \%$ .

# 10.6 Endogenous Interference

Endogenous interference studies were performed according to CLSI EP07-A2. Sample pools for each matrix $( { \sim } 6 0 ~ \mathsf { p g / m L }$ cTnI) were spiked with potential interferents. Control samples were prepared by spiking sample pools with the appropriate diluent at the same volume as the interfering substance stock. For substances spiked at doses that caused $> 1 0 \%$ interference, serial measurements were taken and analyzed by linear regression. Results are presented below.

<table><tr><td rowspan=1 colspan=1>Endogenous Substance</td><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>ControlDose(pg/mL)</td><td rowspan=1 colspan=1>TestDose(pg/mL)</td><td rowspan=1 colspan=1>% Interference</td></tr><tr><td rowspan=2 colspan=1>Bilirubin (Conjugated)40 mg/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>58.08</td><td rowspan=1 colspan=1>57.14</td><td rowspan=1 colspan=1>-1.61%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>59.24</td><td rowspan=1 colspan=1>57.95</td><td rowspan=1 colspan=1>-2.17%</td></tr><tr><td rowspan=2 colspan=1>Bilirubin (Unconjugated)60 mg/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>58.78</td><td rowspan=1 colspan=1>58.75</td><td rowspan=1 colspan=1>-0.06%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>58.87</td><td rowspan=1 colspan=1>58.26</td><td rowspan=1 colspan=1>-1.04%</td></tr><tr><td rowspan=2 colspan=1>Biotin3500 ng/mL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>59.16</td><td rowspan=1 colspan=1>58.86</td><td rowspan=1 colspan=1>-0.51%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>59.40</td><td rowspan=1 colspan=1>59.57</td><td rowspan=1 colspan=1>0.28%</td></tr><tr><td rowspan=2 colspan=1>Cholesterol500 mg/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>50.33</td><td rowspan=1 colspan=1>51.90</td><td rowspan=1 colspan=1>3.12%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>51.45</td><td rowspan=1 colspan=1>51.47</td><td rowspan=1 colspan=1>0.04%</td></tr><tr><td rowspan=2 colspan=1>Hemoglobin500 mg/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>57.29</td><td rowspan=1 colspan=1>56.55</td><td rowspan=1 colspan=1>-1.29%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>58.10</td><td rowspan=1 colspan=1>55.31</td><td rowspan=1 colspan=1>-4.81%</td></tr><tr><td rowspan=2 colspan=1>Protein (Albumin)6 g/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>57.57</td><td rowspan=1 colspan=1>56.18</td><td rowspan=1 colspan=1>-2.40%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>57.64</td><td rowspan=1 colspan=1>58.36</td><td rowspan=1 colspan=1>1.25%</td></tr><tr><td rowspan=2 colspan=1>Protein (Gamma Globulin)2.5 g/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>53.44</td><td rowspan=1 colspan=1>53.28</td><td rowspan=1 colspan=1>-0.30%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>52.68</td><td rowspan=1 colspan=1>54.78</td><td rowspan=1 colspan=1>3.99%</td></tr><tr><td rowspan=2 colspan=1>Protein (Total)12 g/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>54.89</td><td rowspan=1 colspan=1>57.35</td><td rowspan=1 colspan=1>4.48%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>57.04</td><td rowspan=1 colspan=1>56.33</td><td rowspan=1 colspan=1>-1.25%</td></tr><tr><td rowspan=2 colspan=1>Triglycerides2000 mg/dL</td><td rowspan=1 colspan=1>Li Hep</td><td rowspan=1 colspan=1>51.83</td><td rowspan=1 colspan=1>52.05</td><td rowspan=1 colspan=1>0.43%</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>52.20</td><td rowspan=1 colspan=1>51.84</td><td rowspan=1 colspan=1>-0.70%</td></tr></table>

# 10.7 Drug Interference

Therapeutic drug interference studies were performed according to CLSI EP07-A2. Sample pools $( { \sim } 6 0 ~ \mathsf { p g / m L }$ cTnI) for each matrix were tested. Control samples were prepared by spiking sample pools with the appropriate diluent at the same volume as the interfering substance stock. At the tested concentrations, all drugs caused $< 1 0 \%$ interference on the Atellica IM TnIH assay.

<table><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Low Concentration</td><td colspan="1" rowspan="1">High Concentration</td></tr><tr><td colspan="1" rowspan="1">Abciximab</td><td colspan="1" rowspan="1">5 μg/mL</td><td colspan="1" rowspan="1">40 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">20 μg/mL</td><td colspan="1" rowspan="1">200 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">261 μg/mL</td><td colspan="1" rowspan="1">652 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Allopurinol</td><td colspan="1" rowspan="1">13 μg/mL</td><td colspan="1" rowspan="1">40 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Amiodarone</td><td colspan="1" rowspan="1">1.8 μg/mL</td><td colspan="1" rowspan="1">6.1 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Ampicilin</td><td colspan="1" rowspan="1">10 μg/mL</td><td colspan="1" rowspan="1">53 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">12 μg/mL</td><td colspan="1" rowspan="1">60 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Atenolol</td><td colspan="1" rowspan="1">1.1 μg/mL</td><td colspan="1" rowspan="1">10 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">12 μg/mL</td><td colspan="1" rowspan="1">60 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Captopril</td><td colspan="1" rowspan="1">1.0 μg/mL</td><td colspan="1" rowspan="1">5.0 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">120 μg/mL</td><td colspan="1" rowspan="1">660 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Cinnarizine</td><td colspan="1" rowspan="1">200 ng/mL</td><td colspan="1" rowspan="1">400 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Clopidogrel</td><td colspan="1" rowspan="1">37.5 μg/mL</td><td colspan="1" rowspan="1">75 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Cocaine</td><td colspan="1" rowspan="1">0.1 μg/mL</td><td colspan="1" rowspan="1">10 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">1.4 ng/mL</td><td colspan="1" rowspan="1">6.1 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Digitoxin</td><td colspan="1" rowspan="1">30 ng/mL</td><td colspan="1" rowspan="1">60 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Diltiazem</td><td colspan="1" rowspan="1">0.2 μg/mL</td><td colspan="1" rowspan="1">6.2 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Disopyramide</td><td colspan="1" rowspan="1">3.5 μg/mL</td><td colspan="1" rowspan="1">10 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Dopamine</td><td colspan="1" rowspan="1">0.3 μg/mL</td><td colspan="1" rowspan="1">0.9 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Doxycycline</td><td colspan="1" rowspan="1">10.0 μg/mL</td><td colspan="1" rowspan="1">30 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">11 μg/mL</td><td colspan="1" rowspan="1">60 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">20 μg/mL</td><td colspan="1" rowspan="1">60 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">40 μg/mL</td><td colspan="1" rowspan="1">500 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Isosorbide Dinitrate</td><td colspan="1" rowspan="1">50 ng/mL</td><td colspan="1" rowspan="1">150 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">0.10 μg/mL</td><td colspan="1" rowspan="1">0.30 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Lovastatin</td><td colspan="1" rowspan="1">40 ng/mL</td><td colspan="1" rowspan="1">80 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Low MW Heparin</td><td colspan="1" rowspan="1">6.75 U/mL</td><td colspan="1" rowspan="1">30 U/mL</td></tr><tr><td colspan="1" rowspan="1">Methotrexate</td><td colspan="1" rowspan="1">546 μg/mL</td><td colspan="1" rowspan="1">910 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Methyldopa</td><td colspan="1" rowspan="1">4.2 μg/mL</td><td colspan="1" rowspan="1">15 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Methylprednisolone</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">40 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Mexiletine</td><td colspan="1" rowspan="1">1.3 μg/mL</td><td colspan="1" rowspan="1">4.0 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">37 ng/mL</td><td colspan="1" rowspan="1">1000 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">125 ng/mL</td><td colspan="1" rowspan="1">400 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Nitrofurantoin</td><td colspan="1" rowspan="1">2.0 μg/mL</td><td colspan="1" rowspan="1">4.0 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Nitroglycerine</td><td colspan="1" rowspan="1">7.5 ng/mL</td><td colspan="1" rowspan="1">160 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">24 μg/mL</td><td colspan="1" rowspan="1">97 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">12 μg/mL</td><td colspan="1" rowspan="1">50 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Primidone</td><td colspan="1" rowspan="1">10.5 μg/mL</td><td colspan="1" rowspan="1">40 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Propanolol</td><td colspan="1" rowspan="1">0.50 μg/mL</td><td colspan="1" rowspan="1">2.0 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Quinidine</td><td colspan="1" rowspan="1">3.7 μg/mL</td><td colspan="1" rowspan="1">12 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Simvastatin</td><td colspan="1" rowspan="1">16 μg/mL</td><td colspan="1" rowspan="1">32 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">12 μg/mL</td><td colspan="1" rowspan="1">40 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Thyroxine</td><td colspan="1" rowspan="1">0.08 μg/mL</td><td colspan="1" rowspan="1">1.01 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Tissue Plasminogen Activator</td><td colspan="1" rowspan="1">1.15 μg/mL</td><td colspan="1" rowspan="1">2.3 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim</td><td colspan="1" rowspan="1">12 μg/mL</td><td colspan="1" rowspan="1">40 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">0.33 μg/mL</td><td colspan="1" rowspan="1">2.0 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Warfarin</td><td colspan="1" rowspan="1">2.0 μg/mL</td><td colspan="1" rowspan="1">10 μg/mL</td></tr></table>

# 10.8 Cross-Reactivity

Cross-reactivity studies were performed using two sample pools per matrix of approximately $0 \ : \mathsf { p g } / \mathsf { m L }$ and $6 0 ~ \mathsf { p g / m L }$ cTnI. These sample pools were spiked with potential cross-reactants. Control samples were prepared by spiking sample pools with the appropriate diluent at the same volume as the interfering substance stock. Results are presented below.

<table><tr><td colspan="1" rowspan="1">PotentialCross-ReactingSubstance</td><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">cTnlLevel</td><td colspan="1" rowspan="1">ControlDose(pg/mL)</td><td colspan="1" rowspan="1">TestDose(pg/mL)</td><td colspan="1" rowspan="1">% Cross-Reactivity</td></tr><tr><td colspan="1" rowspan="4">Actin</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.47</td><td colspan="1" rowspan="1">1.22</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">56.28</td><td colspan="1" rowspan="1">55.18</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.04</td><td colspan="1" rowspan="1">1.22</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">56.31</td><td colspan="1" rowspan="1">55.29</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="4">Cardiac Troponin T</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.40</td><td colspan="1" rowspan="1">21.71</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.38</td><td colspan="1" rowspan="1">75.92</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1">22.26</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.56</td><td colspan="1" rowspan="1">78.49</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="4">CK-MB</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.57</td><td colspan="1" rowspan="1">1.90</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.92</td><td colspan="1" rowspan="1">56.65</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.18</td><td colspan="1" rowspan="1">1.32</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">54.12</td><td colspan="1" rowspan="1">55.37</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="4">Myoglobin</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.16</td><td colspan="1" rowspan="1">1.39</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.43</td><td colspan="1" rowspan="1">55.05</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.28</td><td colspan="1" rowspan="1">1.03</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.61</td><td colspan="1" rowspan="1">54.65</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="4">Myosin Light Chain</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.36</td><td colspan="1" rowspan="1">1.23</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.39</td><td colspan="1" rowspan="1">55.79</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1">1.09</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">53.90</td><td colspan="1" rowspan="1">53.30</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="4">Skeletal Troponin I</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.59</td><td colspan="1" rowspan="1">0.96</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.52</td><td colspan="1" rowspan="1">53.55</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">0.48</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">53.90</td><td colspan="1" rowspan="1">54.76</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="4">Tropomyosin</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.47</td><td colspan="1" rowspan="1">1.04</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">56.22</td><td colspan="1" rowspan="1">56.31</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">1.01</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">54.15</td><td colspan="1" rowspan="1">54.56</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="4">Troponin C</td><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.64</td><td colspan="1" rowspan="1">13.51</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Li Hep</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">56.26</td><td colspan="1" rowspan="1">69.65</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Zero</td><td colspan="1" rowspan="1">1.12</td><td colspan="1" rowspan="1">15.38</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Low</td><td colspan="1" rowspan="1">55.45</td><td colspan="1" rowspan="1">69.16</td><td colspan="1" rowspan="1">0.00%</td></tr></table>

# 10.9 Heterophile Interference

Heterophile interference studies were performed using lithium heparin plasma and serum spiked with high RF samples, and serum spiked with high HAMA samples. Control samples were prepared by spiking sample pools with the appropriate diluent at the same volume as the interfering substance stock. No interference with HAMA or RF was observed.

# 10.10 High-Sensitivity Designation

The International Federation of Clinical Chemistry (IFCC) Task Force on Clinical Applications of Cardiac Bio-Markers defines a high-sensitivity troponin test as one that meets the following analytical criteria:1

1. $\%$ CV at the ${ 9 9 } ^ { \mathrm { t h } }$ percentile value should be $\leq 1 0 \%$   
2. Measurable concentrations should be attainable at a concentration above the LoD for at least $50 \%$ of healthy individuals

The Atellica IM TnIH assay meets both of these criteria.

# 10.11 Method Comparison with Predicate Device

Not applicable.

# 10.12 Matrix Comparison

Not applicable. All performance studies were performed in all applicable matrices (lithium heparin plasma and serum).

# 10.13 Clinical Studies

A clinical performance study was conducted to evaluate the diagnostic accuracy of the Atellica IM TnIH assay in terms of the clinical concordance between the $9 9 ^ { \mathrm { t h } }$ percentile cutoff and the presence or absence of an adjudicated acute myocardial infarction (AMI) diagnosis. Specimens were collected at 29 sites from different regions across the United States. Testing of specimens was performed at 3 sites.

In this study, the sites enrolled all patients who presented to the emergency department, or ambulatory care center equivalent, with signs or symptoms suspicious for a possible acute coronary syndrome (ACS) event. The diagnosis of AMI was performed by an independent adjudication committee which included cardiologists. The adjudication was based on the Third universal definition of myocardial infarction consensus guideline endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF).

The clinical concordance study evaluated clinical sensitivity, clinical specificity, positive predictive value (PPV) and negative predictive value (NPV) of the Atellica IM TnIH assay in terms of its correlation to the diagnosis of AMI.

Results were analyzed according to time from presentation to the emergency department.

Using the female-specific ${ 9 9 } ^ { \mathrm { t h } }$ percentiles for lithium heparin plasma $( 3 4 . 1 1 ~ { \mathsf { p g / m L } } )$ and serum $( 3 8 . 6 4 ~ \mathsf { p g / m L } )$ , the following results were obtained.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Sensitivity</td><td rowspan=1 colspan=3>Specificity</td><td rowspan=1 colspan=3>PPV</td><td rowspan=1 colspan=3>NPV</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Timepoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=8 colspan=1>Li HepPlasma</td><td rowspan=1 colspan=1>0-1.5hr</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>84.4%</td><td rowspan=1 colspan=1>71.2-92.3</td><td rowspan=1 colspan=1>401</td><td rowspan=1 colspan=1>93.5%</td><td rowspan=1 colspan=1>90.7-95.5</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>59.4%</td><td rowspan=1 colspan=1>47.1-70.5</td><td rowspan=1 colspan=1>382</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=1>96.3- 99.1</td></tr><tr><td rowspan=1 colspan=1>≥1.5-2.5 hr</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>89.9%</td><td rowspan=1 colspan=1>81.3- 94.8</td><td rowspan=1 colspan=1>720</td><td rowspan=1 colspan=1>91.8%</td><td rowspan=1 colspan=1>89.6- 93.6</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>54.6%</td><td rowspan=1 colspan=1>46.0- 62.9</td><td rowspan=1 colspan=1>669</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>97.7- 99.4</td></tr><tr><td rowspan=1 colspan=1>≥2.5-3.5 hr</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>94.5%</td><td rowspan=1 colspan=1>86.7- 97.8</td><td rowspan=1 colspan=1>621</td><td rowspan=1 colspan=1>91.6%</td><td rowspan=1 colspan=1>89.2- 93.6</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>57.0%</td><td rowspan=1 colspan=1>48.1- 65.5</td><td rowspan=1 colspan=1>573</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>98.2- 99.7</td></tr><tr><td rowspan=1 colspan=1>≥3.5-4.5 hr</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>94.0%</td><td rowspan=1 colspan=1>83.8- 97.9</td><td rowspan=1 colspan=1>487</td><td rowspan=1 colspan=1>89.5%</td><td rowspan=1 colspan=1>86.5-91.9</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>48.0%</td><td rowspan=1 colspan=1>38.3- 57.7</td><td rowspan=1 colspan=1>439</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>98.0- 99.8</td></tr><tr><td rowspan=1 colspan=1>≥4.5-6 hr</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>81.1- 99.3</td><td rowspan=1 colspan=1>238</td><td rowspan=1 colspan=1>87.0%</td><td rowspan=1 colspan=1>82.1-90.7</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>44.6%</td><td rowspan=1 colspan=1>32.4-57.6</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>97.3-99.9</td></tr><tr><td rowspan=1 colspan=1>≥6-9 hr</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>94.2%</td><td rowspan=1 colspan=1>86.0- 97.7</td><td rowspan=1 colspan=1>374</td><td rowspan=1 colspan=1>88.0%</td><td rowspan=1 colspan=1>84.3- 90.9</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>59.1%</td><td rowspan=1 colspan=1>49.7- 67.8</td><td rowspan=1 colspan=1>333</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>97.0- 99.5</td></tr><tr><td rowspan=1 colspan=1>≥9-24 hr</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>86.9- 97.9</td><td rowspan=1 colspan=1>342</td><td rowspan=1 colspan=1>87.4%</td><td rowspan=1 colspan=1>83.5- 90.5</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>61.9%</td><td rowspan=1 colspan=1>52.7- 70.4</td><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>96.7- 99.5</td></tr><tr><td rowspan=1 colspan=1>≥24 hr</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>81.7- 99.3</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>80.9%</td><td rowspan=1 colspan=1>72.6- 87.2</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>55.3%</td><td rowspan=1 colspan=1>41.2- 68.6</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>94.0- 99.8</td></tr><tr><td rowspan=8 colspan=1>Serum</td><td rowspan=1 colspan=1>0-1.5hr</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>81.0%</td><td rowspan=1 colspan=1>66.7- 90.0</td><td rowspan=1 colspan=1>407</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>90.8- 95.6</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>56.7%</td><td rowspan=1 colspan=1>44.1- 68.4</td><td rowspan=1 colspan=1>389</td><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=1>96.0- 99.0</td></tr><tr><td rowspan=1 colspan=1>≥1.5-2.5 hr</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>89.6%</td><td rowspan=1 colspan=1>80.8- 94.6</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>92.0%</td><td rowspan=1 colspan=1>89.7- 93.7</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>54.3%</td><td rowspan=1 colspan=1>45.7- 62.7</td><td rowspan=1 colspan=1>671</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>97.7- 99.4</td></tr><tr><td rowspan=1 colspan=1>≥2.5-3.5 hr</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>92.5%</td><td rowspan=1 colspan=1>83.7- 96.8</td><td rowspan=1 colspan=1>619</td><td rowspan=1 colspan=1>92.4%</td><td rowspan=1 colspan=1>90.0- 94.2</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>56.9%</td><td rowspan=1 colspan=1>47.5- 65.8</td><td rowspan=1 colspan=1>577</td><td rowspan=1 colspan=1>99.1%</td><td rowspan=1 colspan=1>98.0- 99.6</td></tr><tr><td rowspan=1 colspan=1>≥3.5-4.5 hr</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>93.8%</td><td rowspan=1 colspan=1>83.2- 97.9</td><td rowspan=1 colspan=1>484</td><td rowspan=1 colspan=1>90.3%</td><td rowspan=1 colspan=1>87.3- 92.6</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>48.9%</td><td rowspan=1 colspan=1>38.9- 59.0</td><td rowspan=1 colspan=1>440</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>98.0- 99.8</td></tr><tr><td rowspan=1 colspan=1>≥4.5-6 hr</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>81.1- 99.3</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>87.7%</td><td rowspan=1 colspan=1>82.9-91.3</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>46.3%</td><td rowspan=1 colspan=1>33.7- 59.4</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>97.3-99.9</td></tr><tr><td rowspan=1 colspan=1>≥6-9 hr</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>86.9- 98.4</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1>88.6%</td><td rowspan=1 colspan=1>85.0-91.4</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>58.3%</td><td rowspan=1 colspan=1>48.6- 67.3</td><td rowspan=1 colspan=1>338</td><td rowspan=1 colspan=1>99.1%</td><td rowspan=1 colspan=1>97.4-99.7</td></tr><tr><td rowspan=1 colspan=1>≥9-24 hr</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>94.5%</td><td rowspan=1 colspan=1>86.7- 97.8</td><td rowspan=1 colspan=1>342</td><td rowspan=1 colspan=1>89.5%</td><td rowspan=1 colspan=1>85.8- 92.3</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>65.7%</td><td rowspan=1 colspan=1>56.2- 74.1</td><td rowspan=1 colspan=1>310</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>96.7- 99.5</td></tr><tr><td rowspan=1 colspan=1>≥24 hr</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>81.1- 99.3</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>82.9%</td><td rowspan=1 colspan=1>74.8- 88.8</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>56.8%</td><td rowspan=1 colspan=1>42.2- 70.3</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>94.2- 99.8</td></tr></table>

Using the male-specific ${ 9 9 } ^ { \mathrm { t h } }$ percentiles for lithium heparin plasma $( 5 3 . 4 8 \ p g / \mathrm { m L } )$ and serum $( 5 3 . 5 3 \mathsf { p g / m L } )$ , the following results were obtained.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Sensitivity</td><td rowspan=1 colspan=3>Specificity</td><td rowspan=1 colspan=3>PPV</td><td rowspan=1 colspan=3>NPV</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Timepoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=8 colspan=1>Li HepPlasma</td><td rowspan=1 colspan=1>0-1.5hr</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>65.7- 82.5</td><td rowspan=1 colspan=1>563</td><td rowspan=1 colspan=1>91.5%</td><td rowspan=1 colspan=1>88.9- 93.5</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>61.0%</td><td rowspan=1 colspan=1>52.1- 69.1</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>93.3- 96.8</td></tr><tr><td rowspan=1 colspan=1>≥1.5-2.5 hr</td><td rowspan=1 colspan=1>161</td><td rowspan=1 colspan=1>87.6%</td><td rowspan=1 colspan=1>81.6- 91.8</td><td rowspan=1 colspan=1>905</td><td rowspan=1 colspan=1>91.2%</td><td rowspan=1 colspan=1>89.1- 92.8</td><td rowspan=1 colspan=1>221</td><td rowspan=1 colspan=1>63.8%</td><td rowspan=1 colspan=1>57.3- 69.9</td><td rowspan=1 colspan=1>845</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>96.4-98.5</td></tr><tr><td rowspan=1 colspan=1>≥2.5-3.5 hr</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>89.8%</td><td rowspan=1 colspan=1>83.4- 94.0</td><td rowspan=1 colspan=1>748</td><td rowspan=1 colspan=1>90.0%</td><td rowspan=1 colspan=1>87.6- 91.9</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>60.5%</td><td rowspan=1 colspan=1>53.4- 67.2</td><td rowspan=1 colspan=1>686</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>96.8- 98.9</td></tr><tr><td rowspan=1 colspan=1>≥3.5-4.5 hr</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>90.9%</td><td rowspan=1 colspan=1>83.6- 95.1</td><td rowspan=1 colspan=1>593</td><td rowspan=1 colspan=1>92.2%</td><td rowspan=1 colspan=1>89.8- 94.1</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>66.2%</td><td rowspan=1 colspan=1>57.9- 73.6</td><td rowspan=1 colspan=1>556</td><td rowspan=1 colspan=1>98.4%</td><td rowspan=1 colspan=1>97.0- 99.1</td></tr><tr><td rowspan=1 colspan=1>≥4.5-6 hr</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>92.5%</td><td rowspan=1 colspan=1>80.1- 97.4</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>90.6%</td><td rowspan=1 colspan=1>86.0- 93.8</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>63.8%</td><td rowspan=1 colspan=1>50.9- 74.9</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>98.5%</td><td rowspan=1 colspan=1>95.8- 99.5</td></tr><tr><td rowspan=1 colspan=1>≥6-9 hr</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>91.1%</td><td rowspan=1 colspan=1>84.8- 95.0</td><td rowspan=1 colspan=1>531</td><td rowspan=1 colspan=1>88.5%</td><td rowspan=1 colspan=1>85.5- 91.0</td><td rowspan=1 colspan=1>174</td><td rowspan=1 colspan=1>64.9%</td><td rowspan=1 colspan=1>57.6-71.6</td><td rowspan=1 colspan=1>481</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>96.0- 98.7</td></tr><tr><td rowspan=1 colspan=1>≥9-24 hr</td><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>88.3- 96.6</td><td rowspan=1 colspan=1>493</td><td rowspan=1 colspan=1>85.6%</td><td rowspan=1 colspan=1>82.2- 88.4</td><td rowspan=1 colspan=1>203</td><td rowspan=1 colspan=1>65.0%</td><td rowspan=1 colspan=1>58.2-71.3</td><td rowspan=1 colspan=1>431</td><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=1>96.1-98.9</td></tr><tr><td rowspan=1 colspan=1>≥24 hr</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>91.4%</td><td rowspan=1 colspan=1>77.6- 97.0</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>88.1%</td><td rowspan=1 colspan=1>81.8- 92.4</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>65.3%</td><td rowspan=1 colspan=1>51.3-77.1</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>93.4- 99.2</td></tr><tr><td rowspan=8 colspan=1>Serum</td><td rowspan=1 colspan=1>0-1.5hr</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>77.6%</td><td rowspan=1 colspan=1>68.3- 84.7</td><td rowspan=1 colspan=1>573</td><td rowspan=1 colspan=1>91.6%</td><td rowspan=1 colspan=1>89.1- 93.6</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>61.3%</td><td rowspan=1 colspan=1>52.5- 69.4</td><td rowspan=1 colspan=1>547</td><td rowspan=1 colspan=1>96.0%</td><td rowspan=1 colspan=1>94.0- 97.3</td></tr><tr><td rowspan=1 colspan=1>≥1.5-2.5 hr</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>86.4%</td><td rowspan=1 colspan=1>80.3- 90.9</td><td rowspan=1 colspan=1>925</td><td rowspan=1 colspan=1>91.5%</td><td rowspan=1 colspan=1>89.5- 93.1</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>63.9%</td><td rowspan=1 colspan=1>57.4- 70.0</td><td rowspan=1 colspan=1>868</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>96.2- 98.3</td></tr><tr><td rowspan=1 colspan=1>≥2.5-3.5 hr</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>87.5%</td><td rowspan=1 colspan=1>80.7- 92.2</td><td rowspan=1 colspan=1>765</td><td rowspan=1 colspan=1>89.9%</td><td rowspan=1 colspan=1>87.6-91.9</td><td rowspan=1 colspan=1>189</td><td rowspan=1 colspan=1>59.3%</td><td rowspan=1 colspan=1>52.1- 66.0</td><td rowspan=1 colspan=1>704</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>96.3- 98.6</td></tr><tr><td rowspan=1 colspan=1>≥3.5-4.5 hr</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>88.9%</td><td rowspan=1 colspan=1>81.2- 93.7</td><td rowspan=1 colspan=1>599</td><td rowspan=1 colspan=1>92.5%</td><td rowspan=1 colspan=1>90.1-94.3</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>66.2%</td><td rowspan=1 colspan=1>57.8- 73.7</td><td rowspan=1 colspan=1>565</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>96.5- 98.9</td></tr><tr><td rowspan=1 colspan=1>≥4.5-6 hr</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>94.7%</td><td rowspan=1 colspan=1>82.7- 98.5</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>86.3- 94.0</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>64.3%</td><td rowspan=1 colspan=1>51.2- 75.5</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>96.4- 99.7</td></tr><tr><td rowspan=1 colspan=1>≥6-9 hr</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>91.0%</td><td rowspan=1 colspan=1>84.6- 94.9</td><td rowspan=1 colspan=1>526</td><td rowspan=1 colspan=1>89.9%</td><td rowspan=1 colspan=1>87.1-92.2</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>67.7%</td><td rowspan=1 colspan=1>60.2- 74.4</td><td rowspan=1 colspan=1>484</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>96.0- 98.7</td></tr><tr><td rowspan=1 colspan=1>≥9-24 hr</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>88.2- 96.6</td><td rowspan=1 colspan=1>499</td><td rowspan=1 colspan=1>85.6%</td><td rowspan=1 colspan=1>82.2- 88.4</td><td rowspan=1 colspan=1>203</td><td rowspan=1 colspan=1>64.5%</td><td rowspan=1 colspan=1>57.7-70.8</td><td rowspan=1 colspan=1>436</td><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=1>96.1- 98.9</td></tr><tr><td rowspan=1 colspan=1>≥24 hr</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>86.5%</td><td rowspan=1 colspan=1>72.0- 94.1</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>88.9%</td><td rowspan=1 colspan=1>82.7-93.0</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>52.5- 78.3</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>91.5-98.4</td></tr></table>

Using the overall $9 9 ^ { \mathrm { t h } }$ Percentile $4 5 . 2 0 \ : \mathsf { p g / m L } )$ , the following results were obtained for both genders combined.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Sensitivity</td><td rowspan=1 colspan=3>Specificity</td><td rowspan=1 colspan=3>PPV</td><td rowspan=1 colspan=3>NPV</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Timepoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=8 colspan=1>Li HepPlasma</td><td rowspan=1 colspan=1>0-1.5hr</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>77.2%</td><td rowspan=1 colspan=1>69.8- 83.3</td><td rowspan=1 colspan=1>964</td><td rowspan=1 colspan=1>91.9%</td><td rowspan=1 colspan=1>90.0- 93.5</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>58.9%</td><td rowspan=1 colspan=1>51.8- 65.7</td><td rowspan=1 colspan=1>919</td><td rowspan=1 colspan=1>96.4%</td><td rowspan=1 colspan=1>95.0- 97.4</td></tr><tr><td rowspan=1 colspan=1>≥1.5-2.5 hr</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>90.0%</td><td rowspan=1 colspan=1>85.6- 93.2</td><td rowspan=1 colspan=1>1625</td><td rowspan=1 colspan=1>90.6%</td><td rowspan=1 colspan=1>89.1- 92.0</td><td rowspan=1 colspan=1>368</td><td rowspan=1 colspan=1>58.7%</td><td rowspan=1 colspan=1>53.6- 63.6</td><td rowspan=1 colspan=1>1497</td><td rowspan=1 colspan=1>98.4%</td><td rowspan=1 colspan=1>97.6- 98.9</td></tr><tr><td rowspan=1 colspan=1>≥2.5-3.5 hr</td><td rowspan=1 colspan=1>201</td><td rowspan=1 colspan=1>92.0%</td><td rowspan=1 colspan=1>87.5- 95.0</td><td rowspan=1 colspan=1>1369</td><td rowspan=1 colspan=1>90.6%</td><td rowspan=1 colspan=1>88.9- 92.0</td><td rowspan=1 colspan=1>314</td><td rowspan=1 colspan=1>58.9%</td><td rowspan=1 colspan=1>53.4- 64.2</td><td rowspan=1 colspan=1>1256</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>97.9-99.2</td></tr><tr><td rowspan=1 colspan=1>≥3.5-4.5 hr</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>92.6%</td><td rowspan=1 colspan=1>87.3- 95.8</td><td rowspan=1 colspan=1>1080</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>89.0- 92.4</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>58.2%</td><td rowspan=1 colspan=1>51.9- 64.3</td><td rowspan=1 colspan=1>992</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>98.0- 99.4</td></tr><tr><td rowspan=1 colspan=1>≥4.5-6 hr</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>89.6- 99.2</td><td rowspan=1 colspan=1>461</td><td rowspan=1 colspan=1>89.2%</td><td rowspan=1 colspan=1>86.0-91.7</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>56.1%</td><td rowspan=1 colspan=1>47.0- 64.9</td><td rowspan=1 colspan=1>413</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>98.3- 99.9</td></tr><tr><td rowspan=1 colspan=1>≥6-9 hr</td><td rowspan=1 colspan=1>193</td><td rowspan=1 colspan=1>92.7%</td><td rowspan=1 colspan=1>88.2- 95.6</td><td rowspan=1 colspan=1>905</td><td rowspan=1 colspan=1>87.6%</td><td rowspan=1 colspan=1>85.3- 89.6</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>61.5%</td><td rowspan=1 colspan=1>55.8- 66.9</td><td rowspan=1 colspan=1>807</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>97.1- 99.0</td></tr><tr><td rowspan=1 colspan=1>≥9-24 hr</td><td rowspan=1 colspan=1>215</td><td rowspan=1 colspan=1>94.0%</td><td rowspan=1 colspan=1>89.9- 96.4</td><td rowspan=1 colspan=1>835</td><td rowspan=1 colspan=1>86.6%</td><td rowspan=1 colspan=1>84.1- 88.7</td><td rowspan=1 colspan=1>314</td><td rowspan=1 colspan=1>64.3%</td><td rowspan=1 colspan=1>58.9- 69.4</td><td rowspan=1 colspan=1>736</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=1>97.0- 99.0</td></tr><tr><td rowspan=1 colspan=1>≥24 hr</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>93.5%</td><td rowspan=1 colspan=1>84.6- 97.5</td><td rowspan=1 colspan=1>253</td><td rowspan=1 colspan=1>83.4%</td><td rowspan=1 colspan=1>78.3- 87.5</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>58.0%</td><td rowspan=1 colspan=1>48.2- 67.2</td><td rowspan=1 colspan=1>215</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>95.3- 99.3</td></tr><tr><td rowspan=8 colspan=1>Serum</td><td rowspan=1 colspan=1>0-1.5hr</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>78.6%</td><td rowspan=1 colspan=1>71.1- 84.6</td><td rowspan=1 colspan=1>980</td><td rowspan=1 colspan=1>92.2%</td><td rowspan=1 colspan=1>90.4- 93.8</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>59.1%</td><td rowspan=1 colspan=1>52.0- 65.9</td><td rowspan=1 colspan=1>934</td><td rowspan=1 colspan=1>96.8%</td><td rowspan=1 colspan=1>95.5- 97.7</td></tr><tr><td rowspan=1 colspan=1>≥1.5-2.5 hr</td><td rowspan=1 colspan=1>239</td><td rowspan=1 colspan=1>87.9%</td><td rowspan=1 colspan=1>83.1- 91.4</td><td rowspan=1 colspan=1>1646</td><td rowspan=1 colspan=1>91.0%</td><td rowspan=1 colspan=1>89.5- 92.3</td><td rowspan=1 colspan=1>358</td><td rowspan=1 colspan=1>58.7%</td><td rowspan=1 colspan=1>53.5- 63.6</td><td rowspan=1 colspan=1>1527</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>97.3- 98.7</td></tr><tr><td rowspan=1 colspan=1>≥2.5-3.5 hr</td><td rowspan=1 colspan=1>195</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>85.9- 94.1</td><td rowspan=1 colspan=1>1384</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>89.1- 92.2</td><td rowspan=1 colspan=1>305</td><td rowspan=1 colspan=1>58.0%</td><td rowspan=1 colspan=1>52.4- 63.4</td><td rowspan=1 colspan=1>1274</td><td rowspan=1 colspan=1>98.6%</td><td rowspan=1 colspan=1>97.8- 99.1</td></tr><tr><td rowspan=1 colspan=1>≥3.5-4.5 hr</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>91.2%</td><td rowspan=1 colspan=1>85.5- 94.8</td><td rowspan=1 colspan=1>1083</td><td rowspan=1 colspan=1>91.0%</td><td rowspan=1 colspan=1>89.1- 92.5</td><td rowspan=1 colspan=1>232</td><td rowspan=1 colspan=1>57.8%</td><td rowspan=1 colspan=1>51.3- 63.9</td><td rowspan=1 colspan=1>998</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>97.8- 99.2</td></tr><tr><td rowspan=1 colspan=1>≥4.5-6 hr</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>96.9%</td><td rowspan=1 colspan=1>89.3- 99.1</td><td rowspan=1 colspan=1>454</td><td rowspan=1 colspan=1>89.6%</td><td rowspan=1 colspan=1>86.5- 92.1</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>56.9%</td><td rowspan=1 colspan=1>47.5- 65.8</td><td rowspan=1 colspan=1>409</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>98.2- 99.9</td></tr><tr><td rowspan=1 colspan=1>≥6-9 hr</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>93.5%</td><td rowspan=1 colspan=1>89.0- 96.3</td><td rowspan=1 colspan=1>904</td><td rowspan=1 colspan=1>88.7%</td><td rowspan=1 colspan=1>86.5- 90.6</td><td rowspan=1 colspan=1>275</td><td rowspan=1 colspan=1>62.9%</td><td rowspan=1 colspan=1>57.1- 68.4</td><td rowspan=1 colspan=1>814</td><td rowspan=1 colspan=1>98.5%</td><td rowspan=1 colspan=1>97.4- 99.2</td></tr><tr><td rowspan=1 colspan=1>≥9-24 hr</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>93.9%</td><td rowspan=1 colspan=1>89.8- 96.4</td><td rowspan=1 colspan=1>841</td><td rowspan=1 colspan=1>86.7%</td><td rowspan=1 colspan=1>84.2- 88.8</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>64.1%</td><td rowspan=1 colspan=1>58.6- 69.2</td><td rowspan=1 colspan=1>742</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=1>97.0- 99.0</td></tr><tr><td rowspan=1 colspan=1>≥24 hr</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>90.5%</td><td rowspan=1 colspan=1>80.7-95.6</td><td rowspan=1 colspan=1>255</td><td rowspan=1 colspan=1>85.5%</td><td rowspan=1 colspan=1>80.6- 89.3</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>60.6%</td><td rowspan=1 colspan=1>50.5- 69.9</td><td rowspan=1 colspan=1>224</td><td rowspan=1 colspan=1>97.3%</td><td rowspan=1 colspan=1>94.3-98.8</td></tr></table>

# 510(k) Summary of Safety and Effectiveness

# 10.14 Traceability and Value Assignment

The Atellica IM TnIH assay is standardized to an internal standard manufactured using human heart homogenate. Assigned values for calibrators are traceable to this standardization.

# 10.15 Stability

The Atellica IM TnIH reagents and calibrators are stable until the date printed on the box label when stored at ${ 2 / 8 ^ { \circ } \mathsf { C } }$ .

The onboard stability of the Atellica IM TnIH reagents is 28 days with a pack calibration interval of 31 days, and a lot calibration interval of 47 days.

# 11. Conclusions

The Atellica IM High-Sensitivity Troponin I (TNIH) assay (Reagents and Calibrators) is substantially equivalent in principle and performance to the currently-marketed predicate device, the Elecsys Troponin T Gen 5 STAT Immunoassay, cleared under 510(k) K162895.